UBS AM
TCRR

UBS AM’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

UBS AM’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,500
Closed -$298K – 2789
2021
Q1 		$298K Sell
13,500
-5,500
-29% -$150K ﹤0.01% 2486
2020
Q4 		$588K Buy
+19,000
New +$480K ﹤0.01% 2245

Other funds holding TCRR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

UBS AM's TCRR Position: Q2 2021 in Review

UBS AM sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2021, closing a stake of 13,500 shares — an estimated $298K sold.

UBS AM first reported a position in TCRR in Q4 2020 and held it in 2 quarters. The position peaked at $588K in Q4 2020. 119 funds tracked by Wall St. Rank hold TCRR as of Q2 2021.

  • UBS AM reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • UBS AM sold 13,500 TCR2 Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $298K.
  • UBS AM first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • UBS AM's TCR2 Therapeutics Inc. Common Stock position peaked at $588K in Q4 2020.
  • 119 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2021.

Based on UBS AM's 13F filing for Q2 2021, filed 16 Aug 2021.